Abstract:Subsequently to the publication of the above article, and a Corrigendum that has already been published with the intention of showing corrected versions of Figs. 1 and 8 (DOI: 10.3892/or.2022.8348; published online on June 14, 2022), the authors have belatedly realized that the revisions made to Fig. 8 necessitated changes that should have been introduced into Fig. 9, although these were not attended to in the first corrigendum. Essentially, Fig. 8 was revised as the cell apoptosis and cell proliferation assays therein were poorly presented, which made the interpretation of the data difficult; Fig. 9 showed the fractions of apoptotic cells in the SKM‑1 and THP‑1 cell lines with lncENST00000444102 overexpression as this pertained to Fig. 8. A revised version of Fig. 9, presenting the analysis of the data shown in the revised version of Fig. 8, is shown opposite. In addition to the revision of Fig. 9, the sentence starting on p. 517, left‑hand column, line 12 [“The flow cytometric apoptosis assay revealed that lncENST00000444102 overexpression promoted tumor cells to undergo apoptosis compared to control cells (P<0.001, Fig. 9)”] should be replaced with the following text, to reflect the change in the level of statistical significance: ‘The flow cytometric apoptosis assay revealed that lncENST00000444102 overexpression promoted tumor cells to undergo apoptosis compared to control cells (P<0.01, Fig. 9)”. Note that the revisions made to Figs. 8 and 9 in this paper have not had a major impact on the reported results, and do not affect the overall conclusions reported in the study. All the authors agree to the publication of this corrigendum. The authors are grateful to the Editor of Oncology Reports for allowing them the opportunity to publish this additional Corrigendum; furthermore, they apologize for any inconvenience caused to the readership of the Journal. [Oncology Reports 42: 509‑520, 2019; DOI: 10.3892/or.2019.7175]

Correction: Corrigendum: Long Intergenic Non-Coding RNA 271 is Predictive of a Poorer Prognosis of Papillary Thyroid Cancer

Correction To: MiRNA-195-5p Functions As a Tumor Suppressor and a Predictive of Poor Prognosis in Non-small Cell Lung Cancer by Directly Targeting CIAPIN1

Correction To: Early Presence of Anti-Angiogenesis-related Adverse Events As a Potential Biomarker of Antitumor Efficacy in Metastatic Gastric Cancer Patients Treated with Apatinib: a Cohort Study

Corrigendum: Identification of an immune-related gene prognostic index for predicting survival and immunotherapy efficacy in papillary renal cell carcinoma

Corrigendum: Long-range RNA Pairings Contribute to Mutually Exclusive Splicing

Corrigendum: A Prognostic Model Based on Immune-Related Long Non-Coding RNAs for Patients With Cervical Cancer

Correction: Corrigendum: Identification of novel PKD1 and PKD2 mutations in a Chinese population with autosomal dominant polycystic kidney disease

Corrigendum: Identification and validation of a novel senescence-related biomarker for thyroid cancer to predict the prognosis and immunotherapy

Corrigendum: Comprehensive transcriptomic analysis of critical RNA regulation associated with metabolism and prognosis in clear cell renal carcinoma

Corrigendum for “lncrna EPB41L4A-AS1 Regulates Glycolysis and Glutaminolysis by Mediating Nucleolar Translocation of HDAC2” [ebiomedicine 41 (2019) 200–213]

Correction: Corrigendum: Identification of High-Quality Cancer Prognostic Markers and Metastasis Network Modules

Corrigendum: Association between diagnostic efficacy of acoustic radiation force impulse for benign and malignant thyroid nodules and the presence or absence of non-papillary thyroid cancer: A meta-analysis

Corrigendum to “ARMCX Family Gene Expression Analysis and Potential Prognostic Biomarkers for Prediction of Clinical Outcome in Patients with Gastric Carcinoma”

[Corrigendum] Role of 4‑aminobutyrate Aminotransferase (ABAT) and the Lncrna Co‑expression Network in the Development of Myelodysplastic Syndrome

Corrigendum: Long non-coding RNA AL139385.1 as a novel prognostic biomarker in lung adenocarcinoma

Correction to: LncRNA PVT1 up-regulation is a poor prognosticator and serves as a therapeutic target in esophageal adenocarcinoma

Publisher Correction: Precise targeting of POLR2A as a therapeutic strategy for human triple negative breast cancer (Nature Nanotechnology, (2019), 14, 4, (388-397), 10.1038/s41565-019-0381-6)

ERRATUM: Mutational landscape of non-functional adrenocortical adenomas

[Corrigendum] miR‐27a‐3p regulates the inhibitory influence of endothelin 3 on the tumorigenesis of papillary thyroid cancer cells

Publisher Correction: Precise targeting of POLR2A as a therapeutic strategy for human triple negative breast cancer

Tumor Necrosis Factor-308 Polymorphism with the Risk and Prognosis of Non-Hodgkin Lymphomas: a Meta-Analysis Study [Corrigendum]